EP2545939

BIOMARIN PHARMACEUTICAL INC.
Application Number
EP12005352A
Filing Date
Apr 11, 2008
Status
Revoked
Jul 7, 2023
Grant Date
Dec 16, 2020
External Links
Slate, Register

Biblio Summary

The patent EP2545939B1 was granted on Dec 16, 2020 by Biomarin Pharmaceutical Inc. The patent is currently Revoked.

The table below shows 5 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

CORIPHARMA EHF.Sep 16, 2021ADMISSIBLE
BETAPHARM ARZNEIMITTEL GMBHSep 15, 2021ADMISSIBLE
STADASep 14, 2021ADMISSIBLE
TEVASep 14, 2021WITHDRAWN
DIPHARMA S.A.Jul 13, 2021WITHDRAWN

The table below shows the patents of Biomarin Pharmaceutical Inc. that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3461503Methods Of Administering Tetrahydrobiopterin, Associated Compositions, And Methods Of MeasuringMay 11, 20225
EP3138566Treatment Of Phenylketonuria With Bh4Jan 26, 20223
EP3175863Variants Of C-Type Natriuretic PeptideDec 1, 20211

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.